Bifunctional drug derivatives of MAO-B inhibitor rasagiline and iron chelator VK-28 as a more effective approach to treatment of brain ageing and ageing neurodegenerative diseases.

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Mechanisms of Ageing and Development

• Publication date

  2005-02-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/J.MAD.2004.08.023PMID 15621213
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): Report of the Consortium on DLB International Workshop

  2006cited by this paper
• Ironing Iron Out in Parkinson's Disease and Other Neurodegenerative Diseases with Iron Chelators: A Lesson from 6‐Hydroxydopamine and Iron Chelators, Desferal and VK‐28

  2004cited by this paper
• Neuroprotection via pro‐survival protein kinase C isoforms associated with Bcl‐2 family members

  2004cited by this paper
• Regulation of protein kinase C by the anti‐Parkinson drug, MAO‐B inhibitor, rasagiline and its derivatives, in vivo

  2004cited by this paper
• Contrasting neuroprotective and neurotoxic actions of respective metabolites of anti-Parkinson drugs rasagiline and selegiline.

  2004cited by this paper
• Is the forced swimming test a suitable model for revealing antidepressant activity?

  2004cited by this paper
• The FAD binding sites of human monoamine oxidases A and B.

  2004cited by this paper
• A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease.

  2004cited by this paper
• Dementia with Lewy bodies.

  2004cited by this paper
• Neuroprotection by a novel brain permeable iron chelator, VK-28, against 6-hydroxydopamine lession in rats.

  2004cited by this paper
• Novel bifunctional drugs targeting monoamine oxidase inhibition and iron chelation as an approach to neuroprotection in Parkinson’s disease and other neurodegenerative diseases

  2004cited by this paper
• Attenuation of MPTP‐induced dopaminergic neurotoxicity by TV3326, a cholinesterase‐monoamine oxidase inhibitor

  2003cited by this paper
• A novel cholinesterase and brain-selective monoamine oxidase inhibitor for the treatment of dementia comorbid with depression and Parkinson's disease.

  2003cited by this paper
• Neuroprotection by deprenyl and other propargylamines: glyceraldehyde-3-phosphate dehydrogenase rather than monoamine oxidase B

  2003cited by this paper
• Anti-apoptotic action of anti-Alzheimer drug, TV3326 [(N-propargyl)-(3R)-aminoindan-5-yl]-ethyl methyl carbamate, a novel cholinesterase-monoamine oxidase inhibitor.

  2003cited by this paper
• The importance of propargylamine moiety in the anti‐ Parkinson drug rasagiline and its derivatives for MAPK‐ dependent amyloid precursor protein processing

  2003cited by this paper
• Rasagiline: an anti-Parkinson drug with neuroprotective activity

  2003cited by this paper
• Propargylamines induce antiapoptotic new protein synthesis in serum- and nerve growth factor (NGF)-withdrawn, NGF-differentiated PC-12 cells.

  2002cited by this paper
• Effect of TV3326, a novel monoamine-oxidase cholinesterase inhibitor, in rat models of anxiety and depression

  2002cited by this paper
• Novel dual inhibitors of AChE and MAO derived from hydroxy aminoindan and phenethylamine as potential treatment for Alzheimer's disease.

  2002cited by this paper
• Mapping the Progress of Alzheimer’s and Parkinson’s Disease

  2002cited by this paper
• Limited potentiation of blood pressure response to oral tyramine by brain-selective monoamine oxidase A-B inhibitor, TV-3326 in conscious rabbits.

  2002cited by this paper
• A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study.

  2002cited by this paper
• The involvement of mitogen‐activated protein (MAP) kinase in the regulation of amyloid precursor protein processing by novel cholinesterase inhibitors derived from rasagiline

  2002cited by this paper
• Selective inhibitors of butyrylcholinesterase: a valid alternative for therapy of Alzheimer's disease?

  2001cited by this paper
• Transfection‐enforced Bcl‐2 overexpression and an anti‐Parkinson drug, rasagiline, prevent nuclear accumulation of glyceraldehyde‐3‐phosphate dehydrogenase induced by an endogenous dopaminergic neurotoxin, N‐methyl(R)salsolinol

  2001cited by this paper
• Antiapoptotic Properties of Rasagiline, N‐Propargylamine‐1(R)‐aminoindan, and Its Optical (S)‐Isomer, TV1022

  2001cited by this paper
• The neuronal MAP kinase cascade: a biochemical signal integration system subserving synaptic plasticity and memory

  2001cited by this paper
• The Anti‐Parkinson Drug Rasagiline and Its Cholinesterase Inhibitor Derivatives Exert Neuroprotection Unrelated to MAO Inhibition in Cell Culture and in Vivo

  2001cited by this paper
• Rasagiline [N‐propargyl‐1R(+)‐aminoindan], a selective and potent inhibitor of mitochondrial monoamine oxidase B

  2001cited by this paper
• Impaired cerebral glucose metabolism and cognitive functioning predict deterioration in mild cognitive impairment

  2001cited by this paper
• Rivastigmine in subcortical vascular dementia: a comparison trial on efficacy and tolerability for 12 months follow‐up

  2001cited by this paper
• Molecular Basis of Neuroprotective Activities of Rasagiline and the Anti-Alzheimer Drug TV3326 [lpar;N-Propargyl-(3R) Aminoindan-5-YL)-Ethyl Methyl Carbamate]

  2001cited by this paper
• Dementia With Lewy Bodies Treated With Rivastigmine: Effects on Cognition, Neuropsychiatric Symptoms, and Sleep

  2001cited by this paper
• Comparison of extrapyramidal signs in dementia with Lewy bodies and Parkinson's disease.

  2001cited by this paper
• Neuroprotective Effects of Novel Cholinesterase Inhibitors Derived from Rasagiline as Potential Anti‐Alzheimer Drugs

  2001cited by this paper
• Selective Inhibitors of Butyrylcholinesterase

  2001cited by this paper
• Comparison of Extrapyramidal Signs in Dementia With Lewy Bodies and Parkinson's Disease

  2001cited by this paper
• Effects of R- and S-apomorphine on MPTP-induced nigro-striatal dopamine neuronal loss.

  2001cited by this paper
• Mechanism underlying anti-apoptotic activity of a (-)deprenyl-related propargylamine, rasagiline.

  2000cited by this paper
• Rivastigmine, a New‐Generation Cholinesterase Inhibitor for the Treatment of Alzheimer's Disease

  2000cited by this paper
• Development of a novel neuroprotective drug (TV3326) for the treatment of Alzheimer's disease, with cholinesterase and monoamine oxidase inhibitory activities

  2000cited by this paper
• Neurotoxins induce apoptosis in dopamine neurons: protection by N-propargylamine-1(R)- and (S)-aminoindan, rasagiline and TV1022.

  2000cited by this paper
• Enhancing effect of rasagiline on superoxide dismutase and catalase activities in the dopaminergic system in the rat.

  2000cited by this paper
• TV3326, a novel neuroprotective drug with cholinesterase and monoamine oxidase inhibitory activities for the treatment of Alzheimer's disease.

  2000cited by this paper
• The prevalence of depression in Alzheimer's disease and vascular dementia in a population sample.

  1999cited by this paper
• N-methyl(R)salsolinol, a dopamine neurotoxin, in Parkinson's disease.

  1999cited by this paper
• The Future of Neuroprotection

  1999cited by this paper
• The Pivotal Role of Iron in NF‐κB Activation and Nigrostriatal Dopaminergic Neurodegeneration: Prospects for Neuroprotection in Parkinson's Disease with Iron Chelators

  1999cited by this paper
• Rasagiline, a monoamine oxidase‐B inhibitor, protects NGF‐differentiated PC12 cells against oxygen‐glucose deprivation

  1999cited by this paper
• Neuroprotective effect of rasagiline, a selective monoamine oxidase-B inhibitor, against closed head injury in the mouse.

  1999cited by this paper
• Pharmacology of rasagiline (N-propargyl-1R-aminoindan).

  1999cited by this paper
• An evaluation of the role of mitochondria in neurodegenerative diseases: mitochondrial mutations and oxidative pathology, protective nuclear responses, and cell death in neurodegeneration.

  1999cited by this paper
• Effects of N-propargyl-1-(R)aminoindan (rasagiline) in models of motor and cognition disorders.

  1998cited by this paper
• Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB)

  1996cited by this paper
• The occurrence of depression in Parkinson's disease. A community-based study.

  1996cited by this paper
• Decreased Catalase Activity but Unchanged Superoxide Dismutase Activity in Brains of Patients with Dementia of Alzheimer Type

  1995cited by this paper
• Increased monoamine oxidase B activity in plaque-associated astrocytes of Alzheimer brains revealed by quantitative enzyme radioautography.

  1994cited by this paper
• Cortical Cytochrome Oxidase Activity Is Reduced in Alzheimer's Disease

  1994cited by this paper
• Decreased concentrations of GLUT1 and GLUT3 glucose transporters in the brains of patients with Alzheimer's disease

  1994cited by this paper
• The Iron Chelator Desferrioxamine (Desferal) Retards 6‐Hydroxydopamine‐Induced Degeneration of Nigrostriatal Dopamine Neurons

  1991cited by this paper
• Senile dementia of Lewy body type: A clinically and neuropathologically distinct form of Lewy body dementia in the elderly

  1990cited by this paper
• Abnormalities of the electron transport chain in idiopathic parkinson's disease

  1989cited by this paper
• Possible neurotransmitter basis of behavioral changes in alzheimer's disease

  1988cited by this paper
• Prevention of MPTP-induced neurotoxicity by AGN-1133 and AGN-1135, selective inhibitors of monoamine oxidase-B.

  1985cited by this paper
• Modification of blood pressure and nictitating membrane response to sympathetic amines by selective monoamine oxidase inhibitors, types A and B, in the cat

  1985cited by this paper
• TYRAMINE ANTAGONISTIC PROPERTIES OF AGN 1135, AN IRREVERSIBLE INHIBITOR OF MONOAMINE OXIDASE TYPE B

  1981cited by this paper
• SELECTIVE ACETYLENIC ‘SUICIDE’ AND REVERSIBLE INHIBITORS OF MONOAMINE OXIDASE TYPES A AND B

  1981cited by this paper
• Immobility induced by forced swimming in rats: effects of agents which modify central catecholamine and serotonin activity.

  1979cited by this paper

• Ferroptosis associated with secondary brain damage induced by hypertensive underlying biological processes in intracerebral hemorrhage and therapeutic prospects

  2026cites this paper
• Polydopamine nanoparticles restore cognition via targeted dopamine delivery and septo-hippocampal cholinergic activation

  2026cites this paper
• Molecules with alkyne fragment in medicinal chemistry: The path from neurotoxins to drugs

  2025cites this paper
• Exploring avenues for Alzheimer’s drugs: current status and future outlook

  2024cites this paper
• Targeting Biometals in Alzheimer’s Disease with Metal Chelating Agents Including Coumarin Derivatives

  2024cites this paper
• Lewy bodies, iron, inflammation and neuromelanin: pathological aspects underlying Parkinson’s disease

  2023cites this paper
• On the Chemical and Biological Characteristics of Multifunctional Compounds for the Treatment of Parkinson’s Disease

  2023cites this paper
• Inhibition of Protein Aggregation and Endoplasmic Reticulum Stress as a Targeted Therapy for α-Synucleinopathy

  2023cites this paper
• 8-Hydroxyquinolines: A Promising Pharmacophore Potentially Developed as Disease-Modifying Agents for Neurodegenerative Diseases: A Review

  2022cites this paper
• Design, Synthesis, and In Vitro Evaluation of Novel 8-Amino-Quinoline Combined with Natural Antioxidant Acids

  2022cites this paper
• SAR studies of quinoline and derivatives as potential treatments for Alzheimer’s disease

  2022cites this paper
• ATH434 Rescues Pre-motor Hyposmia in a Mouse Model of Parkinsonism

  2022cites this paper
• An Update of Synthetic Approaches and Structure‐Activity Relationships of Various Classes of Human MAO‐B Inhibitors

  2021cites this paper
• Regulation | Monoamine Oxidases

  2021cites this paper
• Perspectives for New and More Efficient Multifunctional Ligands for Alzheimer's Disease Therapy

  2021cites this paper
• Dopamine oxidative deamination

  2021cites this paper
• Parkinson's pharmacological therapy

  2021cites this paper
• Pharmacokinetics and pharmacodynamics of levodopa/carbidopa cotherapies for Parkinson’s disease

  2020cites this paper
• Parkinson’s disease and iron

  2020cites this paper
• Conservative iron chelation for neurodegenerative diseases such as Parkinson’s disease and amyotrophic lateral sclerosis

  2020cites this paper
• Ligands for Alzheimer’s Disease therapy

  2020cites this paper
• Perspectives for New and More Efficient Multifunctional Ligands for Alzheimer′s Disease Therapy

  2020cites this paper
• Safinamide in the treatment of Parkinson's disease.

  2020cites this paper
• Iron Pathophysiology in Friedreich's Ataxia.

  2019cites this paper
• Monoamine Oxidase Inhibitor (MAO-I)-Mediated Neuroprotection for Treating Parkinson’s Disease

  2019cites this paper
• Repurposing of Nitroxoline Drug for the Prevention of Neurodegeneration.

  2019cites this paper
• Unraveling Binding Mechanism of Alzheimer’s Drug Rivastigmine Tartrate with Human Transferrin: Molecular Docking and Multi-Spectroscopic Approach towards Neurodegenerative Diseases

  2019cites this paper
• Monoamine oxidase inhibitors, and iron chelators in depressive illness and neurodegenerative diseases

  2018cites this paper
• Copper Increases Brain Oxidative Stress and Enhances the Ability of 6-Hydroxydopamine to Cause Dopaminergic Degeneration in a Rat Model of Parkinson’s Disease

  2018cites this paper
• α‐Synuclein stimulation of monoamine oxidase‐B and legumain protease mediates the pathology of Parkinson's disease

  2018cites this paper
• A Histological and an Immunohistochemical Study on the Effects of Iron Overdose on the Basal Ganglia of the Adult Albino Rat

  2018cites this paper
• Advances in Multi-Functional Ligands and the Need for Metal-Related Pharmacology for the Management of Alzheimer Disease

  2018cites this paper
• A review on iron chelators as potential therapeutic agents for the treatment of Alzheimer’s and Parkinson’s diseases

  2018cites this paper
• An Overview of Multifunctional Metal Chelators as Potential Treatments for Neurodegenerative Diseases

  2017cites this paper
• Iron Chelation Nanoparticles with Delayed Saturation as an Effective Therapy for Parkinson Disease.

  2017cites this paper
• Functional analysis of lifeguard proteins Faim2 and GRINA in the MPTP mouse model of Parkinson disease

  2017cites this paper
• Fusing Docking Scoring Functions Improves the Virtual Screening Performance for Discovering Parkinson’s Disease Dual Target Ligands

  2017cites this paper
• Multi-targeting Strategies for Alzheimer's Disease Therapeutics: Pros and Cons.

  2017cites this paper
• Lactucopicrin ameliorates oxidative stress mediated by scopolamine-induced neurotoxicity through activation of the NRF2 pathway.

  2016cites this paper
• Synthesis and characterization of 1-pyrindane derivatives as rasagiline analogues

  2016cites this paper
• Neuroprotective effects of multifaceted hybrid agents targeting MAO, cholinesterase, iron and β‐amyloid in ageing and Alzheimer's disease

  2016cites this paper
• Ligand-Based Virtual Screening Using Tailored Ensembles: A Prioritization Tool for Dual A2AAdenosine Receptor Antagonists / Monoamine Oxidase B Inhibitors.

  2016cites this paper
• Inhibitors of MAO-A and MAO-B in Psychiatry and Neurology

  2016cites this paper
• Multi-target therapeutics for neuropsychiatric and neurodegenerative disorders.

  2016cites this paper
• Advancing magnetic resonance imaging for the in vivo detection of iron in neurodegeneration

  2016cites this paper
• Association between sex, systemic iron variation and probability of Parkinson's disease

  2016cites this paper
• Enantiopure synthesis of 7-(1-pyrindanyl)propargyl ethers as rasagiline analogues via chemical or enzymatic resolution of 1-pyrindan-7-ol

  2015cites this paper
• Synthesis of Dopamine, Rotigotin, Ladostigil, Rasagiline Analogues 2-Amino-4,5,6-trimethoxyindane, 1-Amino-5,6,7-trimethoxyindane, and Their Sulfamide Derivatives

  2015cites this paper
• Ameliorating role of rutin on oxidative stress induced by iron overload in hepatic tissue of rats.

  2014cites this paper
• Monoamine oxidase inhibitors: promising therapeutic agents for Alzheimer's disease (Review).

  2014cites this paper
• IRON OVERLOAD-INDUCED HEPATIC OXIDATIVE STRESS IN RATS

  2014cites this paper
• Ameliorating role of rutin on oxidative stress induced by iron overload in hepatic tissue of rats.

  2014cites this paper
• Monoamine oxidase and α-synuclein as targets in Parkinson’s disease therapy

  2014cites this paper
• N‐(furan‐2‐ylmethyl)‐N‐methylprop‐2‐yn‐1‐amine (F2MPA): A Potential Cognitive Enhancer with MAO Inhibitor Properties

  2014cites this paper
• Role of iron in UPS impairment model of Parkinson's disease.

  2014influential citation
• Identification of novel scaffolds for Monoamine oxidase B inhibitors

  2014cites this paper
• Identification of novel monoamine oxidase B inhibitors from ligand based virtual screening

  2014cites this paper
• Specific roles for Group V secretory PLA₂ in retinal iron-induced oxidative stress. Implications for age-related macular degeneration.

  2013cites this paper
• A delicate balance: Iron metabolism and diseases of the brain

  2013cites this paper
• Recent Advances in ALS Research: Perspectives for Personalized Clinical Application

  2013cites this paper
• RUTIN ATTENUATES IRON OVERLOAD-INDUCED HEPATIC OXIDATIVE STRESS IN RATS

  2013cites this paper
• Dual inhibitors of monoamine oxidase and cholinesterase for the treatment of Alzheimer disease.

  2013cites this paper
• Dual targeting of adenosine A(2A) receptors and monoamine oxidase B by 4H-3,1-benzothiazin-4-ones.

  2013cites this paper
• Cognitive Enhancers (Nootropics). Part 3: Drugs Interacting with Targets other than Receptors or Enzymes. Disease-modifying Drugs

  2013cites this paper
• Disease-Modifying Therapies in Alzheimer’s Disease

  2012cites this paper
• What have we learned from the streptozotocin-induced animal model of sporadic Alzheimer’s disease, about the therapeutic strategies in Alzheimer’s research

  2012cites this paper
• Oxidative Stress in Parkinson's Disease; Parallels Between Current Animal Models, Human Studies and Cells

  2012cites this paper
• Synthesis of New Molecules Based on 1-pyrindane Ring as a New Strategy in the Neurodegenerative Diseases Treatment

  2012cites this paper
• Dual inhibition: a novel promising pharmacological approach for different disease conditions

  2011cites this paper
• Oxidative Stress in Alzheimer’s Disease: Pathogenesis, Biomarkers and Therapy

  2011cites this paper
• Targeting monoamine oxidases with multipotent ligands: an emerging strategy in the search of new drugs against neurodegenerative diseases.

  2011cites this paper
• The emergence of designed multiple ligands for neurodegenerative disorders.

  2011cites this paper
• New insights into the pathophysiology of endometriosis: from chronic inflammation to danger signal

  2011cites this paper
• Alzheimer’s Disease and Metal Contamination: Aspects on Genotoxicity

  2011cites this paper
• The Biochemical and Cellular Basis for Nutraceutical Strategies to Attenuate Neurodegeneration in Parkinson’s Disease

  2011cites this paper
• Iron chelation and neuroprotection in neurodegenerative diseases

  2011cites this paper
• Advances in iron chelation: an update

  2011cites this paper
• A strong protective action of guttiferone-A, a naturally occurring prenylated benzophenone, against iron-induced neuronal cell damage.

  2011cites this paper
• Nutrition and human health from a sex-gender perspective.

  2011cites this paper
• Iron and Mechanisms of Neurotoxicity

  2010cites this paper
• Why Do We Need Multifunctional Neuroprotective and Neurorestorative Drugs for Parkinson’s and Alzheimer’s Disorders?**

  2010cites this paper
• Recent advances in amyotrophic lateral sclerosis research: perspectives for personalized clinical application

  2010cites this paper
• The transition metals copper and iron in neurodegenerative diseases.

  2010influential citation
• Why Do We Need Multifunctional Neuroprotective and Neurorestorative Drugs for Parkinson's and Alzheimer's Diseases as Disease Modifying Agents

  2010influential citation
• First stereocontrolled acetylation of a hydroxypropargylpiperidone by lipase CALB

  2010cites this paper
• accumulation in neuronal SH-SY5Y cells part of the long-term adaptation process to iron Upregulation of {gamma}-glutamate-cysteine ligase as

  2009cites this paper
• Medicinal inorganic chemistry approaches to passivation and removal of aberrant metal ions in disease.

  2009cites this paper
• Genetic findings in Parkinson's disease and translation into treatment: a leading role for mitochondria?

  2008cites this paper
• Redox imbalance in Parkinson's disease.

  2008cites this paper
• Iron Chelators as Potential Therapeutic Agents for Parkinson's Disease.

  2008cites this paper
• Metal Concentrations in Plasma and Cerebrospinal Fluid in Patients with Alzheimer’s Disease

  2008cites this paper
• Metal based neurodegenerative diseases - From molecular mechanisms to therapeutic strategies

  2008cites this paper
• A Novel iron-chelating derivative of the neuroprotective peptide NAPVSIPQ shows superior antioxidant and antineurodegenerative capabilities.

  2008cites this paper
• Metals in Alzheimer's and Parkinson's diseases.

  2008cites this paper
• Docosahexaenoic acid‐dependent iron accumulation in oligodendroglia cells protects from hydrogen peroxide‐induced damage

  2008cites this paper
• Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases

  2008cites this paper
• Design and Applications of Bifunctional Small Molecules: Why Two Heads Are Better Than One.

  2008cites this paper
• Upregulation of gamma-glutamate-cysteine ligase as part of the long-term adaptation process to iron accumulation in neuronal SH-SY5Y cells.

  2007cites this paper
• Advances in the treatment of Parkinson's disease.

  2007cites this paper
• Neurorescue activity, APP regulation and amyloid-beta peptide reduction by novel multi-functional brain permeable iron- chelating- antioxidants, M-30 and green tea polyphenol, EGCG.

  2007cites this paper